Investment analysts at Lifesci Capital initiated coverage on shares of Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) in a report released on Monday, Benzinga reports. The brokerage set an “outperform” rating and a $41.00 price target on the stock. Lifesci Capital’s price target would suggest a potential upside of 61.04% from the stock’s current price.
ORKA has been the topic of several other reports. Wedbush started coverage on Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 target price on the stock. Jefferies Financial Group initiated coverage on Oruka Therapeutics in a report on Friday. They issued a “buy” rating and a $40.00 target price for the company. Finally, TD Cowen assumed coverage on Oruka Therapeutics in a report on Monday. They set a “buy” rating on the stock.
Get Our Latest Analysis on Oruka Therapeutics
Oruka Therapeutics Stock Performance
About Oruka Therapeutics
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.
Recommended Stories
- Five stocks we like better than Oruka Therapeutics
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Congress Members Are Buying These 3 Hot Stocks
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity
- What are earnings reports?
- 3 Undervalued Stocks That Are Too Cheap to Ignore Right Now
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.